Vincent Woo is a Cardiology physician. OpenAlex indexes 20 publications with 472 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4309 W Medical Center Dr Ste A200
Mchenry, IL 60050
Telephone
815-759-8070Registry record last updated 22 Oct 2018.
Clinical trials
- Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin
Sponsor: University of Manitoba
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- Stryker CorporationProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
82.1%Beta blocker23.7%Metoprolol Succinate48%Carvedilol35%Metoprolol Tartrate16%Propranolol Hcl2%Part D<11 patientsStatin19.5%Atorvastatin Calcium81%Rosuvastatin Calcium14%Pravastatin Sodium5%Part D≥169 patients+ 12 more classes in this area
Blood & clotting
15.8%Factor Xa inhibitor6.5%Eliquis78%Xarelto22%Part D≥54 patientsP2Y12 inhibitor6.2%Clopidogrel100%Part D≥82 patients+ 2 more classes in this area
Metabolism & gastrointestinal
2.1%Potassium supplement1.2%Potassium Chloride100%Part D≥17 patientsProton pump inhibitor1%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- DEEP LEARNING BASED AUTOMATED OPTICAL COHERENCE TOMOGRAPHY ANALYSIS: A NOVEL TOOL FOR IDENTIFICATION OF CORONARY ARTERY LIPID PLAQUES AND QUANTIFICATION OF FIBROUS CAP THICKNESS
Journal of the American College of Cardiology
2023 - Fibrous Cap Thickness Predicts Stable Coronary Plaque Progression: Early Clinical Validation of a Semiautomated OCT Technology
Journal of the Society for Cardiovascular Angiography & Interventions
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”